Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for ...
Circulating tumor DNA (ctDNA) is a powerful tool in cancer diagnostics that can be measured to assess the presence or absence of molecular residual disease (MRD) in a patient’s blood. Natera, an ...
As oncology drug development becomes more biomarker-driven, the industry is rethinking what meaningful early insight looks like and how it can shape better decisions across the life cycle of a program ...
Measurable or minimal residual disease (MRD) is the presence of very small numbers of tumor cells which may remain in the body following treatment. MRD testing currently has multiple clinical uses ...
Natera (NasdaqGS:NTRA) is expanding its oncology footprint through a CytoDyn partnership focused on real-world ctDNA insights in metastatic colorectal cancer. The company also partnered with Diakonos ...
Cell-free DNA fragmentomics as an enabler of tumor-of-origin classification using a commercial targeted cfDNA panel. cfDNA sequencing as a cutting-edge technology to identify pathogenic germline ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...
Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage disease who appear disease-free after treatment. Follow-up care still relies ...
Researchers hope the resulting datasets will be a resource to help discover how to eliminate persister cells before they can give rise to drug-resistant disease.
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results